23andMe Holding Co.
NASDAQ:ME
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
23andMe Holding Co.
NASDAQ:ME
|
510.6m USD |
Loading...
|
|
| US |
|
CVS Health Corp
NYSE:CVS
|
97.3B USD |
Loading...
|
|
| US |
C
|
Cigna Group
XMUN:CGN
|
63.3B EUR |
Loading...
|
|
| US |
|
Cigna Corp
NYSE:CI
|
74.6B USD |
Loading...
|
|
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
29.3B EUR |
Loading...
|
|
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
24.2B EUR |
Loading...
|
|
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
23.3B USD |
Loading...
|
|
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
22.2B USD |
Loading...
|
|
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
11.9B EUR |
Loading...
|
|
| US |
|
Guardant Health Inc
NASDAQ:GH
|
12.9B USD |
Loading...
|
|
| US |
|
DaVita Inc
NYSE:DVA
|
10.4B USD |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
23andMe Holding Co.
Glance View
23andMe Holding Co. is consumer genetics and research company, which engages to help people access, understand, and benefit from the human genome. The company is headquartered in South San Francisco, California. The company went IPO on 2020-10-06. The firm offers direct-to-consumer genetic testing and personalized information about genetic health risks, ancestry, and traits. The firm operates through two segments: Consumer & Research Services and Therapeutics. Its consumer & research services business segment comprises personal genome service (PGS) and research services. Its PGS provides a suite of genetic reports, including information on genetic ancestral origins, personal genetic health risks, rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. The Company’s therapeutics segment focuses on drug development for discovering and developing therapies to improve patient lives and includes out-licensing of intellectual property. The Company’s programs across therapeutic areas, include oncology, immunology, neurology, metabolic and cardiovascular diseases.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for 23andMe Holding Co. is 52.6%, which is above its 3-year median of 46.5%.
Over the last 3 years, 23andMe Holding Co.’s Gross Margin has increased from 50.2% to 52.6%. During this period, it reached a low of 44.8% on Jun 30, 2024 and a high of 52.6% on Jan 1, 2025.
